Effect of thalidomide affecting VEGF secretion, cell migration, adhesion and capillary tube formation of human endothelial EA.hy 926 cells

Life Sciences

Volumn 78, Issue 22, 2006, Pages 2558-2563

  Komorowski, Jan ^a   Jerczyńska, Hanna ^b   Siejka, Agnieszka ^a   Barańska, Patrycja ^b   Ławnicka, Hanna ^a   Pawłowska, Zofia ^b   Stepień, Henryk ^a  

^a Medical University of Lodz Dr Sterling ^*  (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Angiogenesis; Cell proliferation; EA.hy 926 cells; Thalidomide; VEGF

Indexed keywords

COLLAGEN; THALIDOMIDE; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; PROTEIN SECRETION; SUPERNATANT;

ANGIOGENESIS INHIBITORS; CAPILLARIES; CELL ADHESION; CELL LINE; CELL MOVEMENT; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; HUMANS; THALIDOMIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33646033735     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2005.10.016     Document Type: Article

References (42)

1. Brennen W.N., Cooper C.R., Capitosti S., Brown M.L., and Sikes R.A. Thalidomide and analogues: current proposed mechanisms and therapeutic usage. Clinical Prostate Cancer 3 (2004) 54-61
2. Chambers A.F., and Matrisian L. Changing views of the role of matrix metalloproteinases in metastasis. Journal of the National Cancer Institute 89 (1997) 1260-1270
3. Chintagumpala M., Blaney S.M., Bomgaars L.R., Aleksic A., Kuttesch J.F., Klenke R.A., and Berg S.L. Phase I and pharmakinetic study of thalidomide with carboplatin in children with cancer. Journal of Clinical Oncology 22 (2004) 4394-4400
4. Chua Y.J., Steer C.R., and Yip D. Recent advances in management of small-cell lung cancer. Cancer Treatment Reviews 30 (2004) 521-543
5. D'Amato R.J., Loughnan M.S., Flynn E., and Folkman J. Thalidomide is an inhibitor of angiogenesis. Proceedings of the National Academy of Sciences of the United States of America 91 (1994) 4082-4085
6. Eliseenko V.I., Skobelkin O.K., Chegin V.M., and Degtiarev M.K. Blood microcirculation and angiogenesis in wound healing by first and second intentions. Biulleten' Eksperimental'Noi Biologii i Meditsiny 105 (1988) 243-246
7. Eter N., and Spitznas M. DMSO mimics inhibitory effect of thalidomide on choriocapillary endothelial cell proliferation in culture. The British Journal of Ophthalmology 86 (2002) 1303-1305
8. Eubank T.D., Galloway M., Montague C.M., Waldman W.J., and Marsh C.B. M-CSF induces vascular endothelial growth factor production and angiogenic activity from human monocytes. Journal of Immunology 171 (2003) 2637-2643
9. Fanelli M., Sarmiento R., Gattuso D., Carillio G., Capaccetti B., Vacca A., Roccaro A.M., and Gasparini G. Thalidomide: a new anticancer drug?. Expert Opinion on Investigational Drugs 12 (2003) 1211-1225
10. Ferrara N. VEGF: an update on biological and therapeutic aspects. Current Opinion in Biotechnology 11 (2000) 617-624
11. Ferrara N., and Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nature Medicine 12 (1999) 1359-1364
12. Folkman J. Tumor angiogenesis: therapeutic implications. The New England Journal of Medicine 285 (1971) 1182-1186
13. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Medicine 1 (1995) 27-31
14. Folkman J. Role of angiogenesis in tumor growth and metastasis. Seminars in Oncology 6 Suppl. 16 (2002) 15-18
15. Folkman J., Long D.M., and Becker F.F. Growth and metastasis of tumor in organ culture. Cancer 16 (1963) 453-467
16. Folkman J., Merler E., Abernathy C., and Williams G. Isolation of tumor factor responsible for angiogenesis. The Journal of Experimental Medicine 133 (1971) 275-288
17. Gasparini G. The rationale and future potential of angiogenesis inhibitors in neoplasia. Drugs 58 (1999) 17-38
18. Goldman C.K., Kendall R.L., Cabrera G., Soroceanu L., Heike Y., Gillespie G.Y., Siegal G.P., Mao X., Bett A.J., Huckle W.R., Thomas K.A., and Curiel D.T. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth metastasis, and mortality rate. Proceedings of the National Academy of Sciences of the United States of America 95 (1998) 8795-8800
19. Gordon M.S. Novel antiangiogenic therapies for renal cell cancer. Clinical Cancer Research 10 (2004) 6337S-6381S
20. Hanahan D.A. Flanking attack on cancer. Nature Medicine 5 (1999) 1359-1364
21. Jiang B.H., Agani F., Passaniti A., and Semenza G.L. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Research 57 (1997) 5328-5335
22. Jiang C., Agarwal R., and Lu J. Anti-angiogenic potential of a cancer chemopreventive flavonoid antioxidant, sylimarin: inhibition of key attributes of vascular endothelial growth factor and angiogenic cytokine secretion by cancer epithelial cells. Biochemical and Biophysical Research Communications 276 (2000) 371-378
23. Kahari V.M., and Saarialho-Kere U. Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Annals of Medicine 31 (1999) 34-45
24. Kerbel R., and Folkman J. Clinical translation of angiogenesis inhibitors. Nature Reviews Cancer 2 (2002) 727-739
25. Komorowski J., Jankiewicz J., and Stepien H. Vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and soluble interleukin-2 receptor (sIL-2R) concentrations in peripheral blood as markers of pituitary tumours. Cytobios 101 (2000) 151-159
26. Komorowski J., Pasieka Z., Jankiewicz-Wika J., and Stepien H. Matrix metalloproteinases, tissue inhibitors of matrix metalloproteinases and angiogenic cytokines in peripheral blood of patients with thyroid cancer. Thyroid 12 (2002) 655-662
27. Krupinski J., Kaluza J., Kumar P., Kumar S., and Wang J.M. Role of angiogenesis in patients with cerebral ischemic stroke. Stroke 25 (1994) 1794-1798
28. Lawnicka H., Stepien H., Wyczolkowska J., Kolago B., Kunert-Radek J., and Komorowski J. Effect of somatostatin and octreotide on proliferation and vascular endothelial growth factor secretion from murine endothelial cell line (HECa10) culture. Biochemical and Biophysical Research Communications 268 (2000) 567-571
29. Li X., Liu X., Wang J., Wang Z., Jiang W., Reed E., Zhang Y., Liu Y., and Li Q.Q. Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells. Anticancer Research 23 (2003) 2481-2487
30. Liekens S., de Clerq E., and Neyts J. Angiogenesis: regulators and clinical applications. Biochemical Pharmacology 61 (2001) 253-270
31. Nasca M.R., O'Toole E.A., Palicharla P., West D.P., and Woodley D.T. Thalidomide increase human keratinocyte migration and proliferation. The Journal of Investigative Dermatology 113 (1999) 720-724
32. Ng S.S., Gutschow M., Weiss M., Hauschildt S., Teubert U., Hecker T.K., Luzzio F.A., Kruger A.E., Eger K., and Gigg W.D. Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues. Cancer Research 63 (2003) 3189-3194
33. Norrby U. Angiogenesis: new aspects relating to its initiation and control. APMIS: Acta Pathologica, Microbiologica, et Immunologica Scandinavica 105 (1997) 417-437
34. Pasieka Z., Stepien H., Komorowski J., Kolomecki K., and Kuzdak K. Evaluation of the levels of bFGF, VEGF, sICAM-1, and sVCAM-1 in serum of patients with thyroid cancer. Recent Results in Cancer Research 162 (2003) 189-194
35. Prewett M., Huber J., Li Y., Santiago A., O'Connor W., King K., Overholser J., Hooper A., Pytowski B., Witte L., Bohlen P., and Hicklin D.J. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Research 59 (1999) 5209-5218
36. Randeva H.S., Lewandowski K.C., Komorowski J., Murray R.D., O'Callaghan C.J., Hillhouse E.W., Stepien H., and Shalet S.M. Growth hormone replacement decreases plasma levels of matrix metalloproteinases (2 and 9) and vascular endothelial growth factor in growth hormone-deficient individuals. Circulation 109 (2004) 2405-2410
37. Risau W. Mechanism of angiogenesis. Nature 386 (1997) 671-674
38. Rosinol L., Cibeira M.T., Segarra M., Cid M.C., Filella X., Aymerich M., Rozman M., Arenillas L., Esteve J., Blade J., and Montserrat E. Response of thalidomide in multiple myeloma: impact of angiogenic factors. Cytokine 26 (2004) 145-148
39. Slejifer S., Kruit W.H., and Stoter G. Thalidomide in solid tumours: the resurrection of an old drug. European Journal of Cancer 60 (2004) 2377-2382
40. Slevin M., Kumar S., and Gaffney J. Angiogenic oligosaccharides of hyaluronan induce multiple signaling pathways affecting vascular endothelial cell mitogenic and wound healing responses. The Journal of Biological Chemistry 277 (2002) 41046-41059
41. Stepien H.M., Kolomecki K., Pasieka Z., Komorowski J., Stepien T., and Kuzdak K. Angiogenesis of endocrine gland tumours - new molecular targets in diagnostics and therapy. European Journal of Endocrinology 148 (2002) 143-151
42. Stepien H., Lawnicka H., Siejka A., Mucha S., Gruszka A., Stepien T., Krupinski R., and Komorowski J. Inhibitory effect of thalidomide on VEGF secretion in diethylstilbestrol (DES)-induced prolactinoma in Fisher 344 rats. MEDIMOND. International Proceedings of the 12th International Congress of Endocrinology, Lisbon (Portugal) (2004) 1495-1498 August 31-September 4